Otis Worldwide R&D decreased by 7.3% to $38.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.7%, from $37.00M to $38.00M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a -1.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $39.00M | $39.00M | $46.00M | $37.00M | $38.00M | $37.00M | $38.00M | $35.00M | $36.00M | $36.00M | $37.00M | $36.00M | $39.00M | $40.00M | $37.00M | $37.00M | $38.00M | $36.00M | $41.00M | $38.00M |
| QoQ Change | — | +0.0% | +17.9% | -19.6% | +2.7% | -2.6% | +2.7% | -7.9% | +2.9% | +0.0% | +2.8% | -2.7% | +8.3% | +2.6% | -7.5% | +0.0% | +2.7% | -5.3% | +13.9% | -7.3% |
| YoY Change | — | — | — | — | -2.6% | -5.1% | -17.4% | -5.4% | -5.3% | -2.7% | -2.6% | +2.9% | +8.3% | +11.1% | +0.0% | +2.8% | -2.6% | -10.0% | +10.8% | +2.7% |